NCI’s provocative questions on cancer: some answers to ignite discussion

Mikhail V. Blagosklonny

doi:10.18632/oncotarget.432

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

NCI’s provocative questions on cancer: some answers to ignite discussion

Mikhail V. Blagosklonny _

PDF | HTML | How to cite

Oncotarget. 2011; 2:1352-1367. https://doi.org/10.18632/oncotarget.432

Metrics: PDF 2624 views | HTML 4344 views | ?

Abstract

Mikhail V. Blagosklonny¹

¹Department of Cell Stress Biology, Roswell Park Cancer Institute, BLSC, L3-312, Elm and Carlton Streets, Buffalo, NY, 14263, USA

Received: December 8, 2011; Accepted: December 31, 2011; Published: December 31, 2011;

Keywords: NCI, cancer, therapy, prevention, aging, rapamycin, mTOR

Correspondence:

Mikhail V. Blagosklonny, email:

Abstract

The National Cancer Institute has announced 24 provocative questions on cancer. Why do many cancer cells die when suddenly deprived of a protein encoded by an oncogene? Can we extend patient survival by using approaches that keep tumors static? Why are some disseminated cancers cured by chemotherapy alone? Can we develop methods to rapidly test interventions for cancer treatment or prevention? Can we use our knowledge of aging to enhance prevention or treatment of cancer? What is the mechanism by which some drugs commonly and chronically used for other indications protect against cancer? How does obesity contribute to cancer risk? Here I try to answer these questions by linking the dots of existing knowledge.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 432

Publication Alerts

Research Perspectives:

NCI’s provocative questions on cancer: some answers to ignite discussion

Abstract